Oppenheimer Asset Management Inc. Trims Stock Holdings in Progyny, Inc. $PGNY

Oppenheimer Asset Management Inc. reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 22.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,057 shares of the company’s stock after selling 7,618 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Progyny were worth $595,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of PGNY. GAMMA Investing LLC lifted its stake in shares of Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock valued at $120,000 after buying an additional 3,768 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Progyny during the 1st quarter worth $354,000. New York State Teachers Retirement System lifted its stake in shares of Progyny by 0.7% during the 1st quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock worth $1,635,000 after purchasing an additional 500 shares during the period. Principal Financial Group Inc. lifted its position in Progyny by 2.9% during the first quarter. Principal Financial Group Inc. now owns 471,826 shares of the company’s stock worth $10,541,000 after buying an additional 13,246 shares during the period. Finally, Cerity Partners LLC grew its holdings in Progyny by 116.9% in the first quarter. Cerity Partners LLC now owns 28,881 shares of the company’s stock valued at $645,000 after purchasing an additional 15,563 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Buying and Selling

In other news, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director directly owned 12,501 shares in the company, valued at approximately $275,522.04. This represents a 16.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,895 shares of company stock worth $179,311 over the last quarter. Insiders own 9.40% of the company’s stock.

Progyny Trading Up 0.3%

PGNY stock opened at $18.71 on Friday. The firm has a market cap of $1.61 billion, a P/E ratio of 31.71, a P/E/G ratio of 1.59 and a beta of 1.34. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76. The stock’s 50 day simple moving average is $21.30 and its 200 day simple moving average is $21.93.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company posted $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of research analyst reports. Canaccord Genuity Group lifted their target price on Progyny from $21.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 20th. Truist Financial boosted their price target on Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Leerink Partners raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price on the stock in a research report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price target on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.